CN111821436B - Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof - Google Patents
Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof Download PDFInfo
- Publication number
- CN111821436B CN111821436B CN202010771037.XA CN202010771037A CN111821436B CN 111821436 B CN111821436 B CN 111821436B CN 202010771037 A CN202010771037 A CN 202010771037A CN 111821436 B CN111821436 B CN 111821436B
- Authority
- CN
- China
- Prior art keywords
- tumor
- targeted
- oxygen
- tlyp
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 128
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000001301 oxygen Substances 0.000 title claims abstract description 67
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 67
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 42
- 238000003745 diagnosis Methods 0.000 title claims abstract description 41
- 230000000149 penetrating effect Effects 0.000 title claims abstract description 38
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 28
- 206010070834 Sensitisation Diseases 0.000 title claims abstract description 17
- 230000008313 sensitization Effects 0.000 title claims abstract description 17
- 238000010276 construction Methods 0.000 title description 3
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 30
- 239000002131 composite material Substances 0.000 claims abstract description 29
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 29
- 230000008685 targeting Effects 0.000 claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 230000035515 penetration Effects 0.000 claims abstract description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Inorganic materials O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 29
- 239000002114 nanocomposite Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 12
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 239000012286 potassium permanganate Substances 0.000 claims description 7
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920002851 polycationic polymer Polymers 0.000 claims description 5
- MRMOMIYVTPUCMS-UHFFFAOYSA-N acetic acid;pyrrolidine-2,5-dione Chemical compound CC(O)=O.O=C1CCC(=O)N1 MRMOMIYVTPUCMS-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 150000004035 chlorins Chemical group 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000006213 oxygenation reaction Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229960005540 iRGD Drugs 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- 238000001338 self-assembly Methods 0.000 claims description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 229960000907 methylthioninium chloride Drugs 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- 206010021143 Hypoxia Diseases 0.000 description 22
- 230000007954 hypoxia Effects 0.000 description 17
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 9
- 238000002189 fluorescence spectrum Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 230000012202 endocytosis Effects 0.000 description 7
- 230000001146 hypoxic effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 239000011572 manganese Substances 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- 102000002111 Neuropilin Human genes 0.000 description 2
- 108050009450 Neuropilin Proteins 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- MWZBTMXISMOMAE-AATRIKPKSA-N (E)-ethyl 3-(2-furyl)acrylate Chemical compound CCOC(=O)\C=C\C1=CC=CO1 MWZBTMXISMOMAE-AATRIKPKSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100267932 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YRB1 gene Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 238000004224 UV/Vis absorption spectrophotometry Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012835 hanging drop method Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 239000007777 multifunctional material Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a targeting penetrating type nano diagnosis and treatment compound for tumor in-situ oxygen generation and sensitization photodynamic curative effect and a preparation method thereof, wherein the nano diagnosis and treatment compound comprises three parts: GO-MnO with graphene oxide as substrate2The tumor targeting homing peptide comprises a composite oxygen-producing carrier, a tumor targeting homing penetrating peptide connected with the carrier, and a photosensitizer carried on the carrier. The nano diagnosis and treatment compound has the functions of tumor targeted deep penetration, tumor microenvironment responsive in-situ oxygen production and MRI/fluorescence imaging, and can greatly improve the curative effect of photodynamic therapy.
Description
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to a targeted penetrating type nano diagnosis and treatment compound for tumor in-situ oxygen generation and sensitization photodynamic curative effect and a preparation method thereof.
Background
Photodynamic therapy (PDT) is a novel noninvasive tumor therapy, and the basic principle is that a photosensitizer accumulated in target cells or tissues is excited by laser with a proper wavelength to perform photochemical reaction, so that the photosensitizer reacts with oxygen molecules to form Reactive Oxygen Species (ROS), thereby generating cytotoxicity to kill tumor cells and achieving the purpose of resisting tumors. Compared with other methods such as chemotherapy, the photodynamic therapy has the advantages of lower toxic and side effects, higher selectivity, minimally invasive high efficiency and the like. Since the 70's of the 20 th century, in clinical applications, PDT has been extensively studied for the treatment of various types of solid tumors and other diseases.
However, further clinical applications of PDT are still limited by a number of troublesome problems. From the principle of the common PD tii type photochemical reaction, it is known that a photosensitizer, oxygen concentration and laser are the most important three elements thereof. Oxygen is one of the most important factors determining ROS production, however, as PDT proceeds, the concentration of oxygen is gradually consumed, eventually inhibiting ROS production instead. In addition to this self-limiting factor, it is well known that the microenvironment inside solid tumors is in a hypoxic state; in most tumors, the percent hypoxia increased from 10% to 30%, with oxygen pressures below 15mm Hg. Therefore, tumor cells regulate a series of tumor growth and metabolic behaviors through hypoxia response regulatory factor (HIF-1), such as promoting expression of glucose transporter (GLUT), promoting glycolysis, and down-regulating the rate of mitochondrial oxidative phosphorylation. Most importantly, hypoxia greatly limits the yield of cytotoxic ROS in PDT, so that cells with strong invasiveness of tumor hypoxia centers cannot be effectively killed, treatment resistance is caused, and tumor drug resistance is caused. In response to this problem, various strategies for alleviating tumor hypoxia have been proposed, such as hyperbaric oxygen injection, microbubble-carried oxygen, reaction of metal with hydrogen peroxide to generate oxygen in situ, perfluorocarbon or hemoglobin-carried oxygen delivery, etc. However, these methods still cannot effectively solve the problem that the PDT treatment effect of tumor is limited by tumor hypoxia, and some methods have the problems of low oxygen carrying efficiency, complex operation, and possibly causing other biological toxicity, so that there is still an urgent need to develop a novel technology to solve this problem.
Currently, MnO2Due to the unique chemical reaction activity, degradability, high biocompatibility and other excellent properties, the nano material has attracted great interest of researchers. (1) Nano MnO2And H2O2Reacting, in particular, with endogenous H in intratumoral acidic environments2O2Reaction, consumption of H+And oxygen is released, in-situ oxygenation in the tumor is directly realized, and the anaerobic state is improved. The results of the study revealed that MnO2NPs are introduced into the nano-drugs, so that the curative effects of radiotherapy, chemotherapy, PDT and the like are greatly improved. (2) Nano MnO2And H2O2Self-decomposed to Mn during the reaction2+,Mn2+Is easily and rapidly discharged by organism, thereby avoiding nano MnO2Aggregation in vivo results in toxicity, and excellent biocompatibility is shown. More importantly, Mn2+It has 5 spin-parallel unpaired electrons and is an excellent Magnetic Resonance Imaging (MRI) contrast agent. (3) Nano MnO2Can also react with glutathione with higher concentration in tumor cells, and can improve the oxidation reduction stress state in tumors. Thus, nano MnO2The MRI probe is an excellent multifunctional material which responds to multiple biochemical characteristics of a tumor microenvironment and specifically generates oxygen in tumor tissues and releases the MRI imaging probe. At each locationMnO of2In the nanomaterial, MnO2NPs have the obvious advantages of simple and rapid synthesis, cheap raw materials, large specific surface area, controllable size, easy compounding with other nano materials and the like, but MnO with smaller particle size2NPs have low drug loading efficiency of photosensitizers, are particularly difficult to compound with hydrophobic photosensitizers, and still need other carrier materials.
On the other hand, the hypoxic state inside the tumor often increases from the tumor margin to the interior of the tumor, solving the problem of tumor hypoxia, and at the same time, the problem of how to deliver the photosensitizer and the oxygen-generating carrier to the hypoxic center of the tumor needs to be considered. Although existing research suggests that nano-drugs can enhance the permeability and retention effect (namely EPR effect) of tumor tissues, photosensitizers (>100nm) are passively targeted to be delivered to tumors; however, due to pathological obstacles such as disordered vascular systems inside the tumor, high interstitial pressure, dense extracellular matrix and the like, the nano photosensitive drug is only gathered around the tumor vessels, is difficult to effectively diffuse in tissues inside the tumor, and cannot reach hypoxic regions, so that the curative effect of the nano photosensitive drug is greatly limited. At present, in order to increase the tumor tissue permeability of nano-drugs, strategies such as modifying tumor homing penetrating peptide on the surface of a nano-carrier or utilizing responsive molecules (such as matrix metalloproteinase and weak acidity) in tumor microenvironment to enable the size of nanoparticles to be disintegrated or gradually reduced in tumor are gradually reported. However, these methods do not simultaneously achieve the problem of improving hypoxia inside the tumor.
Therefore, considering the complicated microenvironment inside the tumor and the gradual deepening of the tumor deep hypoxia, how to improve the PDT therapeutic effect of the tumor from the combined angle of the relaxation of the tumor internal hypoxia and the targeted permeation inside the tumor becomes a problem to be solved by those skilled in the art. Therefore, the construction of the nano-carrier-based targeted penetration type nano diagnosis and treatment system with the tumor in-situ oxygen generation and sensitization photodynamic curative effect has important significance for tumor treatment.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a targeted penetration type nano diagnosis and treatment compound with tumor in-situ oxygen generation and sensitization photodynamic curative effects and a preparation method thereof.
In order to achieve the purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
a targeting penetrating nano diagnosis and treatment compound for in-situ generating oxygen and sensitizing photodynamic therapy effect of tumor comprises GO-MnO with graphene oxide as a substrate2The tumor targeting homing penetration peptide is connected with the composite oxygen-generating carrier in a chemical covalent connection mode, and the photosensitizer is connected with the composite oxygen-generating carrier in a pi-pi accumulation effect, a hydrophobic effect, a hydrogen bond or an electrostatic effect;
wherein, GO-MnO taking graphene oxide as substrate2The composite oxygen-generating carrier is formed by in-situ growth of MnO on the surface of graphene oxide through modification of aminated cations2And (4) preparing the nano particles.
Further, the tumor targeting homing penetrating peptide is LyP-1, F3, iRGD or tLyP-1, preferably tLyP-1.
Further, the photosensitizer is an organic fluorescent dye capable of generating singlet oxygen and capable of being excited by near infrared light (wavelength of 620-1100 nm), specifically chlorins, porphyrins, phthalocyanines, rhodamines, methylene blues, cyanines (such as ICG, IR820 and IR825) and the like, and preferably chlorins (such as Ce 6).
The preparation method of the tumor in-situ oxygen generation sensitization photodynamic therapy targeted penetrating type nano diagnosis and treatment compound comprises the following steps:
(1) synthesis of GO-MnO2Composite oxygen-generating carrier
Carrying out self-assembly or amide reaction on GO and an aminated polycation polymer to prepare a GO-polycation compound, adding a potassium permanganate solution into the GO-polycation compound, and reacting at room temperature for 12-36h to prepare the GO-polycation compound; the mass ratio of polycationic polymer to GO is 0.25: 1-2: 1; the mass ratio of GO to potassium permanganate is 1:8-12, preferably 1: 8.4;
(2) preparation of targeting penetrating oxygen-producing nano composite carrier
Synthesizing FITC-labeled thiolated tumor targeting homing penetrating peptide, and then adding GO-MnO2Mixing the composite oxygen-producing carrier, maleimide polyethylene glycol succinimide acetate and FITC marked sulfhydrylation tumor targeted homing penetrating peptide according to the weight ratio of 1:0.1-1:0.1-1, and reacting at room temperature for 20-28h to obtain the product;
(3) preparation of targeting penetrating nano diagnosis and treatment compound
The photosensitizer and the targeted penetrating oxygen-producing nano composite carrier are self-assembled to prepare the targeted penetrating nano diagnosis and treatment composite.
Further, the aminated polycationic polymer is poly (allylamine hydrochloride) (PAH), polylysine or polyethyleneimine, preferably PAH, with a molecular weight in the range of 15-50.0kDa, preferably 15000, in daltons.
Further, the mass ratio of the aminated polycationic polymer to GO is 1: 1.
Further, the reaction concentration of potassium permanganate is 10-20mM, the reaction concentration of potassium permanganate is preferably 13.3mM, and the reaction time is preferably 24 h.
Further, GO-MnO2The weight ratio of the composite oxygen-generating carrier, the maleimide polyethylene glycol succinimide acetate and the FITC-labeled thiolated tLyP-1 is 1:0.18: 0.18.
Further, the mass ratio of the photosensitizer to the targeted penetration type oxygen production nano composite carrier is 0.1-4: 1.
further, the mass ratio of the photosensitizer to the targeted penetration type oxygen production nano composite carrier is 1: 1.
The targeted penetrating type nano diagnosis and treatment compound for the in-situ oxygen generation and sensitization photodynamic curative effect of the tumor and the preparation method thereof provided by the invention have the following beneficial effects:
the targeted penetrating type nano diagnosis and treatment compound for the in-situ oxygen generation and sensitization photodynamic curative effect of the tumor mainly comprises three parts:GO-MnO with graphene oxide as substrate2The tumor targeting homing peptide comprises a composite oxygen-producing carrier, a tumor targeting homing penetrating peptide connected with the carrier, and a photosensitizer carried on the carrier. GO-MnO with graphene oxide as substrate2The particle size of the graphene oxide in the composite oxygen-generating carrier is 150-500 nm, the surface of the graphene oxide is provided with carboxylic acid residues, hydroxyl and epoxy groups, and the graphene oxide can be functionalized by chemical modification, namely small-size MnO can be grown on the surface of the graphene oxide in situ2The nano particles, and the two-dimensional plane structure and the aromatic structure of the nano particles can carry various medicines, such as photosensitizer, through pi-pi accumulation effect, hydrophobic force effect, hydrogen bond, electrostatic effect and other modes. The tumor targeting homing penetration peptide is a small molecule peptide with unique tumor tissue targeting and penetration capacity, the action mechanism of the tumor targeting homing penetration peptide is mainly a C-end Rule (C-end Rule, CendR) approach, namely, the free C end of the homing penetration peptide must contain (R/K) XX (R/K) motifs which are hidden in a peptide segment; when bound to Receptors (such as integrins) on the surface of tumor cells, the peptides are proteolytically cleaved to expose the cryptic CendR motif, which in turn specifically binds to the b1 domain of Neuropilin Receptors (NRPs) on the surface of target cells, triggering the cells to undergo a specific endocytosis/transcellular transport, transporting the "cargo" carried by the homing peptides deep into the tumor tissue. The photosensitizer is an organic fluorescent dye which can be excited by near infrared light (with the wavelength of 620-1100 nm) and can generate singlet oxygen, and when the photosensitizer is combined on the nano diagnosis and treatment compound, the photosensitizer can be excited to participate in oxygen reaction to generate cytotoxic singlet oxygen. In conclusion, the plane structure and the large specific surface area of GO are utilized, and MnO is grown on the surface of GO in situ through modification of amination cations2The nanoparticle is simultaneously modified with a targeting homing penetrating peptide, and the targeting homing penetrating peptide can be specifically combined with a b1 structural domain of Neuropilin Receptors (NRPs) on the cell surface to trigger cells to generate a special endocytosis/transcellular transport function, so that the cells penetrate into the interior of a three-dimensional ellipsoid, and further target a tumor hypoxia center, a tumor microenvironment and intracellular H in the tumor microenvironment2O2And MnO with MnO2The nano particles react to generate oxygen, thereby slowing downRelieving the hypoxic microenvironment deep in the tumor; then GO through GO-MnO2The pi-pi conjugation and the hydrophobic effect carry the photosensitizer efficiently, the photosensitive compound drug is penetrated through the depth of the tumor in a targeted way, and the photosensitizer is excited to react with oxygen to generate cytotoxic singlet oxygen, so that the hypoxia state in the depth of the tumor can be relieved better, and the curative effect of photodynamic therapy is improved greatly.
The nano composite prepared by the invention also has the functions of tumor microenvironment responsive in-situ oxygen generation and MRI imaging, and specifically comprises the following steps: the nano-composite of the invention utilizes H of the tumor microenvironment2O2Can be in situ with MnO2The nano particles react to generate oxygen and release Mn simultaneously2+The improvement of the anoxic state in the deep part of the tumor can be realized, so that the photodynamic therapy effect is improved, the dosage is reduced, and the toxic and side effects are obviously reduced; at the same time, Mn is used2+Is T1An MRI imaging probe for MRI imaging to detect the targeted accumulation of the nano diagnosis and treatment system in the tumor; meanwhile, the photosensitizer can also be used as a fluorescent probe to carry out fluorescence imaging, the distribution and metabolism conditions of the nano diagnosis and treatment system in each tissue and tumor of a mouse are detected, the photodynamic therapy guided by magnetic resonance/fluorescence imaging can be realized, and the photodynamic therapy efficiency of the tumor is greatly improved. In addition, MnO may be avoided2The nanoparticles aggregate in vivo to generate toxicity, and show excellent biocompatibility.
Based on the advantages, the nano-composite prepared by the invention can be used for treating various solid tumors including but not limited to skin cancer, malignant melanoma, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, liver cancer, breast cancer, laryngeal cancer, thyroid cancer, tongue cancer, prostatic cancer, penile cancer, testicular tumor, vaginal malignant tumor and vulval malignant tumor appearing on the surface or inside of organs. The treatment can be carried out by intratumoral direct administration or intravenous administration.
Drawings
FIG. 1 is GO-MnO2Ultraviolet-visible absorption spectrum and Zeta potential result of the oxygen-generating composite carrier.
FIG. 2 is GO-MnO2Transmission electron microscopy characterization of oxygen-producing composite carriersAnd (6) obtaining the result.
FIG. 3 shows Zeta potential, violet-visible absorption spectrum, fluorescence spectrum and drug loading and encapsulation efficiency of tLyP-1 of GM @ tLyP-1 vector.
FIG. 4 is a schematic structural diagram of GM @ tLyP-1/Ce 6.
FIG. 5 is a graph showing UV-visible absorption spectrum, fluorescence spectrum, Zeta potential and hydrated particle size of GM @ tLyP-1/Ce 6.
FIG. 6 shows the oxygen generating performance and the active oxygen performance characterization results of GM @ tLyP-1/Ce 6.
FIG. 7 is in vitro magnetic resonance imaging T of GM @ tLyP-1/Ce61And (5) imaging performance characterization results.
FIG. 8 shows the results of in vitro cytotoxicity, targeted endocytosis and penetration assay of GM @ tLyP-1/Ce 6.
FIG. 9 shows the in vitro targeting oxygen production enhancing photodynamic anti-cancer effect of GM @ tLyP-1/Ce 6.
FIG. 10 is the results of improved tumor hypoxia in GM @ tLyP-1/Ce 6.
FIG. 11 shows the results of in vivo MRI/FL bimodal imaging of GM @ tLyP-1/Ce 6.
FIG. 12 is the results of GM @ tLyP-1/Ce6 enhancing ROS in vivo.
FIG. 13 shows the in vivo oxygen production enhanced photodynamic anti-tumor results of GM @ tLyP-1/Ce 6.
Detailed Description
Example 1
A targeting penetrating nano diagnosis and treatment compound for in-situ generating oxygen and sensitizing photodynamic therapy effect of tumor comprises GO-MnO with graphene oxide as a substrate2A composite oxygen-generating type carrier is prepared,
tumor targeting homing penetrating peptide connected with the composite oxygen-generating carrier in a chemical covalent connection mode, and photosensitizer connected with the composite oxygen-generating carrier in a pi-pi accumulation effect, a hydrophobic effect, a hydrogen bond or an electrostatic effect, and the preparation process comprises the following steps:
first step, synthesis of GO-MnO2Composite oxygen-generating carrier
Adding 1mL of poly (allylamine hydrochloride) (PAH) solution (with the concentration of 1mg/mL) dropwise into 2mL of graphene oxide solution (with the concentration of 0.5mg/mL) under the condition of magnetic stirring, and reacting overnightTo prepare GO-PAH compound; adding 1mL of potassium permanganate solution (8.4mg/mL) into the GO-PAH compound dropwise, stirring at room temperature overnight, centrifuging the solution at high speed (15000rpm,15min), discarding the supernatant, washing the precipitate with deionized water for three times, adding 0.1mL of deionized water to constant volume to obtain GO-MnO2An oxygen-generating composite carrier.
For the GO-MnO prepared2The oxygen-producing composite carrier is detected as follows:
1. the results of ultraviolet-visible absorption spectrum detection and Zeta potential detection are shown in figure 1. Wherein, fig. 1a is the ultraviolet-visible absorption spectrum detection result, and fig. 1b is the Zeta potential detection result.
From FIG. 1a, GO-MnO2Having MnO in oxygen-generating composite carrier (abbreviated as GM)2Typical UV-visible absorption peaks (300-400 nm); from FIG. 1b, GO-MnO2The Zeta potential of the oxygen-producing composite carrier is reduced from +47.3mV of GO-PAH to +10.8 mV.
2. Transmission electron microscopy characterization
Characterization by transmission electron microscopy, as shown in fig. 2, wherein (a) in fig. 2 is a Transmission Electron Microscopy (TEM) characterization image of GO; (b) TEM image as GM; (c) EDS elemental analysis chart for GM; (d) STEM Mapping element distribution map of GM.
From FIG. 2, GO-MnO2A clear black nanoparticle appears on the TEM image of (A) and confirmed to be MnO by EDS elemental analysis2And (4) NPs. Further proves GO-MnO through STEM Mapping element distribution diagram2The upper C element, the Mn element and the N element are uniformly distributed and almost have no free state, and the GO-MnO is proved2Successful synthesis of oxygen-generating composite carriers.
Secondly, synthesizing a targeting penetrating oxygen-producing nano composite carrier GM @ tLyP-1
0.1mL of GM solution (GM solution concentration 1mg/mL, GM mass 0.1mg) was diluted to 5.0mL with PBS buffer, and 18. mu.g of bifunctional PEG (NHS-PEG-MAL, maleimide polyethylene glycol succinimidyl acetate) and 18. mu.g of FITC-labeled thiolated tLyP-1 were weighed, quickly added to the reaction flask, and stirred at room temperature overnight. After the reaction, the reaction mixture was centrifuged at high speed (15000rpm,15min), and the supernatant was discarded, followed by repeated washing three times to remove unbound NHS-PEG-MAL and tLyP-1. Adding 2mL of deionized water to a constant volume to obtain a GM @ tLyP-1 carrier solution, and storing at 4 ℃.
The GM @ tLyP-1 carrier is characterized by Zeta potential, a purple light-visible absorption spectrum and a fluorescence spectrum, and the characterization result is shown in figure 3. FIG. 3 (a) shows the Zeta potentials of GO, GM and GM @ tLyP-1; (b) is a graph of the ultraviolet-visible absorption spectra of GM, GM @ tLyP-1 and tLyP-1; (c) is a fluorescence spectrum diagram of GM @ tLyP-1 and tLyP-1; (d) the drug loading rate and the encapsulation rate of the tLyP-1 are shown.
Through detecting the Zeta potentials of GO, GM and GM @ tLyP-1, the Zeta potential is further increased to +23mV after the tLyP-1 is connected; while the successful modification of the tLyP-1 is proved by the results of the characteristic peak of the tLyP-1 marked by FITC appearing at 480nm in the ultraviolet-visible absorption spectrum and the characteristic peak of the tLyP-1 marked by FITC appearing at about 518nm in the fluorescence spectrum; the drug loading of tLyP-1 when fully encapsulated was 18% as measured by UV-Vis absorption spectroscopy.
Thirdly, preparing a targeted penetrating nano diagnosis and treatment compound GM @ tLyP-1/Ce6
2mL of GM @ tLyP-1 carrier solution (0.5mg/mL) was added with 1mL of Ce6 solution (1mg/mL) under low-speed magnetic stirring, stirred at room temperature overnight for reaction, centrifuged at high speed (15000rpm,15min), the supernatant was discarded, and washing was repeated three times to remove unbound Ce 6. Adding 2mL of deionized water for constant volume to obtain GM @ tLyP-1/Ce6 nano diagnosis and treatment compound solution, and storing at 4 ℃.
The schematic diagram of the prepared GM @ tLyP-1/Ce6 nano diagnosis and treatment compound is shown in FIG. 4. Then, synthesizing and characterizing the GM @ tLyP-1/Ce6 nano diagnosis and treatment compound by an ultraviolet-visible absorption spectrum, a fluorescence spectrum and a particle size analyzer, wherein the result is shown in figure 5; wherein, (a) is the ultraviolet-visible spectrum of each nano system; (b) the fluorescence spectra of GM @ tLyP-1/Ce6 and Ce 6; (c) zeta potential results for each nanosystem; and (d) is a hydrodynamic diameter and physical diagram of each nano system (an inset, 1 is GO, 2 is GM, 3 is GM @ tLyP-1, and 4 is GM @ tLyP-1/Ce 6).
As shown in FIG. 5a, the final targeting penetrating type nano diagnosis and treatment compound GM @ tLyP-1/Ce6 has a characteristic absorption peak of manganese dioxide near 350nm and characteristic absorption peaks of Ce6 near 404nm and 660nm, and successful synthesis of GM @ tLyP-1/Ce6 is proved; as shown in FIG. 5b, the fluorescence spectrum results show that GM @ tLyP-1/Ce6 shows significant Ce6 fluorescence quenching, which is caused by Ce6 supported on GO, further demonstrating the successful loading of Ce 6. Zeta potential and hydrodynamic diameter measurements were performed by a particle sizer, as shown in FIG. 5c, after loading Ce6, the potential of GM @ tLyP-1/Ce6 changed from +23mV to-26 mV of GM @ tLyP-1, and the hydrodynamic diameter also gradually increased; further, the drug loading rate of GM @ tLyP-1/Ce6 calculated by spectroscopy can reach up to 45%. The above results further confirm the successful synthesis of GM @ tLyP-1/Ce 6.
Example 2 GM @ tLyP-1/Ce6 in vitro oxygen production, singlet oxygen yield, and MRI imaging Performance testing
The performance of the targeted penetrating nano diagnosis and treatment compound prepared by the invention is evaluated mainly by the following method:
1. characterization of oxygen production Properties
An equal amount of 100mg of GM @ tLyP-1/Ce6 solution was reacted with 100. mu.M hydrogen peroxide solution at pH 6.5 and 7.4, respectively, and a blank control was set. The oxygen content of the solution was measured every 10 seconds using a JPBJ-608 portable dissolved oxygen analyzer.
As shown in fig. 6a, at H2O2Solution (100. mu.M) + GM @ tLyP-1/Ce6 group, can rapidly trigger the reaction to produce O2And the oxygen generation rate is remarkably increased along with the increase of acidity, which proves that the GM @ tLyP-1/Ce6 nano-composite has good oxygen generation effect.
2. Characterization of active oxygen Properties
Detecting the singlet oxygen yield of the photosensitizer by adopting a singlet oxygen probe (SOSG), wherein when no singlet oxygen exists, the fluorescence of chromophore is quenched by electron transfer in the molecule of the SOSG; in the presence of singlet oxygen, SOSG forms endoperoxides, which result in a change in electron transfer and a restoration of chromophore fluorescence (530 nm). Therefore, the increase in fluorescence intensity of SOSG at 530nm directly reflects the singlet oxygen production.
In 0.5mL GM @ tLyP-1/Ce6 solution (equiv. [ Ce6 ]]mu.M) was added 0.5. mu.L of a singlet oxygen fluorescent probe SOSG stock solution (final concentration of SOSG of 2.5)Mu M), mixing well, and then using 660nm laser (power is 2W/cm)2) After exciting the solution (0, 2, 4, 6, 8, 10, 12min), the fluorescence emission spectrum at 530nm was detected.
As shown in FIG. 6b, the SOSG signal of the GM @ tLyP-1/Ce6 nanocomposite was gradually increased with the increase of the light irradiation time, which proves that GM @ tLyP-1 has good singlet oxygen yield. However, compared with free Ce6, the fluorescent intensity of SOSG under the same conditions is slightly weaker due to energy transfer between the graphene carrier and Ce6, but can be further used for photodynamic therapy.
3. Detection of in vitro magnetic resonance imaging function
GM @ tLyP-1/Ce6 nanocomposite solutions of different Mn concentrations were fixed in order and placed in a magnetic resonance imager, parameters were adjusted (T1 test: IR sequence, SFO1 ═ 22.106MHz, P1 ═ 16.20 μ s, P2 ═ 32.80 μ s, SW ═ 200KHz, RG1 ═ 20, DRGl ═ 3, PRG ═ 3, TW ═ 25000ms, NTI ═ 30, NS ═ 2), and magnetic resonance imaging images of the samples were examined.
As shown in fig. 7 (each set of bars in fig. 7b represents pH 7.4, pH 6.5 and pH 5.0, respectively, from left to right), it can be observed that as pH decreases and Mn content increases, T increases1The signal becomes clearly brighter. Thus, under acidic conditions, T1The signal is enhanced along with the increase of the Mn concentration, and GM @ tLyP-1/Ce6 has obvious T1-MRI contrast effect.
Example 3 GM @ tLyP-1/Ce6 in vitro cytotoxicity, Targeted endocytosis and penetration experiments
GM @ tLyP-1/Ce6, mouse breast cancer cell 4T1, prepared by the preparation method provided in example 1, was purchased from ATCC and 4T1 cells were cultured using RPMI 1640 medium.
1. Cytotoxicity assay of GM @ tLyP-1 vector
4T1 cells in logarithmic growth phase were seeded in 96-well plates (density 1.0X 10)4Per well), cultured for 24 h. The culture medium in the well plate was removed, different concentrations of GM @ tLyP-1(25.0, 50.0, 100.0, 150.0, 200.0, 250.0. mu.g/mL) were added to the well plate (three wells per concentration were repeated) and incubation was continued for 12 h. The cell culture solution is removed and the cells are cultured,washing was repeated three times with PBS buffer. Add 100. mu.L of prepared CCK-8 working solution to each well and continue incubation for 45 min. Detecting the light absorption value (OD value) at 450nm by a microplate reader, and calculating the cell survival rate according to the formula: survival rate ═ (experimental OD value-blank OD value) - (control OD value-blank OD value).
As shown in FIG. 8a (each column represents 24h and 48h from left to right), the survival rate of 24h and 48h cells after incubation of GM @ tLyP-1 vector with 4T1 cells at different concentrations was 85%, indicating that the vector has no cytotoxicity in a certain range and good biological safety, even if the concentration of the vector is as high as 250. mu.g/mL.
2. Targeted endocytosis capacity of GM @ tLyP-1/Ce6 in two-dimensional cell plane
4T1 cells in logarithmic growth phase were seeded on a confocal culture dish 15mm in diameter (density 6.5X 10)4One/well), three sets were repeated and incubation continued for 24 h. Washed 3 times with PBS buffer, and added with Ce6, GM @ PEG/Ce6, and GM @ tLyP-1/Ce6 nanocomplexes ([ GM ] diluted with cell culture medium]=200μg/mL,[Ce6]9. mu.g/mL)), and the culture was continued for 4 hours. The supernatant was aspirated off, washed 3 times with PBS buffer, cells were fixed with 4% paraformaldehyde, and aspirated off after 20 min. After washing 3 times with PBS buffer, 1mL of cell nuclear staining solution (DAPI) was added to the petri dish and the dish was stained in the dark at room temperature for 5 min. The DAPI stain was discarded and washed 3 times with PBS buffer. The cells were immersed in 1mL PBS buffer, keeping the bottom of the dish free of clear water. Placing the culture dish under a laser confocal microscope for observation, observing by a 40-time oil scope, and respectively detecting DAPI (lambda)Ex=405nm)、Ce6(λEx640 nm).
As shown in FIG. 8b, the green fluorescence of the fluorescent probe FITC labeled on tLyP-1 was observed in the GM @ tLyP-1/Ce6 group, and the red fluorescence of Ce6 was the strongest in the GM @ tLyP-1/Ce6 group compared to the control group; the GM @ tLyP-1/Ce6 nano diagnosis and treatment compound synthesized in the example 1 is shown to have a good targeting endocytosis effect.
3. Transmembrane permeability of GM @ tLyP-1/Ce6 nano diagnosis and treatment compound to three-dimensional tumor spheres
Three-dimensional tumor spheres were constructed by the hanging drop method, and 4T1 cells in the logarithmic growth phase were digested at 20. mu.L per drop (density 1X 10)5one/mL) was added dropwise to the lid of the cell culture dish, 1mL of PBS was added to the dish, the lid was quickly closed, and the plate was placed in an incubator at 37 ± 2 ℃ for 3 days in a hanging manner. Gently flick with medium and transpose into low-adhesion cell culture dishes. Respectively adding a nano diagnosis and treatment compound ([ GM ] GM) containing Ce6, GM @ PEG/Ce6 and GM @ tLyP-1/Ce6]=500μg/mL,[Ce6]22.5 μ g/mL) and endocytosis for 24 h. Transferring to a glass slide, and detecting FITC (lambda) by three-dimensional layer scanning with a confocal laser microscopeEx=488nm)、 Ce6(λEx640 nm).
As shown in FIG. 8c, the GM @ tLyP-1/Ce6 group penetrated into the interior of the tumor sphere through a distance of about 90 μm compared to the control group. And only a few nanoparticles enter the tumor spheres in the non-targeting group and the free Ce6 group, so that the GM @ tLyP-1/Ce6 nano diagnosis and treatment compound has good targeting penetrating capability.
Example 4 in vitro Targeted enhanced tumor photodynamic therapy Effect of GM @ tLyP-1/Ce6
4T1 cells in logarithmic growth phase were seeded in 96-well plates (density 10)4One/well), cultured for 24 h. The old culture medium was removed, washed 3 times with PBS buffer, and cell culture medium diluted Ce6, GO @ tLyP-1/Ce6, GM @ PEG/Ce6, GM @ tLyP-1/Ce6([ GM @ tLyP-1/Ce6) were combined in the following manner]=200μg/mL, [Ce6]Not 9 μ g/mL) solution was added separately to incubate cells for 4 h:
a first group: control; second group: control + Laser; third group: h2O2+H+(ii) a And a fourth group: h2O2+H++Laser。
Removing old culture solution after culturing, washing with PBS buffer solution for 3 times, adding new cell culture solution into the well plate, and using laser with wavelength of 660nm and 0.5W/cm2Irradiating each hole for 5min under the condition of power density. After the light irradiation, the culture was continued for 24 hours, and the old culture solution was removed and washed 3 times with PBS buffer. Each well was added with 100.0. mu.L of CCK8 working solution and incubation was continued for 45 min. Placing the cell pore plate in an enzyme labeling instrument, and setting the detection wavelength to be 4At 50nm, absorbance (OD) was recorded and relative cell viability was calculated.
As shown in FIG. 9 (each set of columns in FIG. 9a represents Ce6, GM @ PEG/Ce6, GO @ tLyP-1/Ce6, and GM @ tLyP-1/Ce6, respectively, from left to right; each set of columns in FIG. 9b represents control, H, respectively, from left to right2O2+H+、Laser、H2O2+H++ Laser; in the absence of a simulated tumor microenvironment, the survival rate of free Ce6 cells reaches about 80%, and the survival rate of 4T1 cells can be reduced to 40% after the Ce6 is combined on the GM @ tLyP-1 vector, which indicates that the GM @ tLyP-1 can enhance the uptake rate of Ce6 by cells. Under the microenvironment simulating tumor acidity and a large amount of hydrogen peroxide, compared with a control group, the survival rate of cells of the GM @ tLyP-1/Ce6 group is reduced to be within 20%, the photodynamic curative effect is improved by nearly 2 times, and the GM @ tLyP-1/Ce6 nano diagnosis and treatment compound has enhanced PDT treatment potential in tumors.
Example 5 study of in vivo tumor hypoxia amelioration of GM @ tLyP-1/Ce6
Balb/c mice are provided by the experimental animal center of Sichuan university, are female, are 5-6 weeks old and have the weight of 18-22 g.
Cells were expanded in vitro, digested and counted, diluted in sterile saline, and 100. mu.L of saline (1X 10) was injected subcutaneously into the right hind leg of mice74T1 cells), the tumor grows to a volume of about 200mm after 8-14 days3Intravenous injections were performed, divided into 4 groups of 2 per group, and blank groups were intratumorally injected with saline as follows: a first group: control (control group); second group: GO @ tLyP-1/Ce6 (Targeted, oxygen-non-generating group); third group: GM @ PEG/Ce6 (non-targeting, oxygen-producing group); and a fourth group: GM @ tLyP-1/Ce6 (Targeted, oxygen-producing group); tail vein injection: each mouse was 100. mu.L ([ MnO ]2]=0.045mg/mL,[Ce6]=0.45mg/mL, [GO]1 mg/mL); after 6 hours of administration, the hypoxic probe pethidine hydrochloride (60mg/kg) was injected intratumorally, and after 90 minutes, the tumors were surgically excised and frozen sections. Tumor sections were incubated with mouse anti-pimozole antibody (1:100 dilution, Hypoxyprobe Inc.) and Alex 488-conjugated goat anti-mouse secondary antibody (1:200 dilution, Jackson Inc.) as per instructions, and nuclei were stained with DAPI, with the results shown in figure 10. FIG. 10 shows the injectionsAfter nanoparticle grouping, DCFH-DA fluorescence signal pattern (sacle bar 50 μm) at the tumor site in mice.
As can be seen from FIG. 10, the tumor tissues in the control group showed a clear green fluorescence signal of the hypoxia probe, indicating that the interior of the solid tumor itself was in a state of severe hypoxia; while the GM @ tLyP-1/Ce6 treated group had a significantly reduced green fluorescence signal and a high degree of co-localization of the green fluorescence signal with the blue fluorescence signal of DAPI, indicating that GM @ tLyP-1/Ce6 could indeed alleviate the tumor hypoxic state.
Example 6 study of GM @ tLyP-1/Ce6 in vivo MRI/FL
The 4T1 tumor-bearing mouse model was constructed and grouped as in example 5 for 4 groups of 3 mice each, and tail vein dosing was performed: 100 μ L ([ MnO ]2]=0.045mg/mL,[Ce6]=0.45mg/mL,[GO]1 mg/mL); after 48h of imaging is finished, the mouse is dissected, fluorescence imaging is carried out on main organs and tumors, and the accumulation condition of the GM @ tLyP-1/Ce6 nano diagnosis and treatment compound is analyzed by detecting the fluorescence of Ce 6.
As shown in fig. 11a, significant mri signal enhancement was detectable at the tumor site relative to the control group. The strongest signal was detected at the tumor site 8h after administration, after which the signal intensity decreased with time, indicating that the GM @ tLyP-1/Ce6 Nanocouch Complex can be used as a T1 contrast agent for magnetic resonance imaging. The group GM @ tLyP-1/Ce6 showed significant distribution at the tumor site 48h after injection (see FIG. 11b), indicating that GM @ tLyP-1/Ce6 indeed enables targeted enrichment of the drug at the tumor site, and has a longer tumor residence time, which is beneficial for the subsequent PDT.
Example 7 GM @ tLyP-1/Ce6 enhanced photodynamic anti-tumor Effect in vivo
1. Detection of ROS production in mice
A tumor-bearing mouse model was constructed as in example 5, and a DCFH-DA solution containing GM @ tLyP-1/Ce6 (intratumoral administration) was injected into the tumor, after which the tumor tissue was collected and frozen and sectioned on a glass slide for fluorescence detection.
As shown in FIG. 12 (bar graphs representing, from left to right, Pre-injection, GO @ tLyP-1/Ce6, GM @ PEG/Ce6, GM @ tLyP-1/Ce6, respectively), there was almost no significant green fluorescence signal at the tumor site due to the inhibition of PDT effect caused by severe hypoxia at the tumor site. In contrast to the control group, the GM @ tLyP-1/Ce6 group showed the strongest green fluorescence signal, representing a large amount of ROS production, and confirmed that the GM @ tLyP-1/Ce6 nanocomposite can indeed enhance PDT effect by generating oxygen.
2. In vivo enhanced photodynamic anti-tumor effect detection
The mouse 4T1 breast cancer cells are cultured in vitro to construct a xenograft tumor-bearing mouse model, and the xenograft tumor-bearing mouse model is divided into 5 mice in groups at random. Blank groups were injected intravenously with 100. mu.L of saline, GM @ tLyP-1/Ce6, GM @ PEG/Ce6, and GO @ tLyP-1/Ce 6. The injection dosage of Ce6 is 90 mug/piece, the injection dosage of GO is 200 mug/piece, MnO is2The injection dose is 9 mug/body; mice were dehaired, exposing the illuminated area. Using a 660nm near-infrared laser at 0.5W/cm2The laser density of (2) is used for irradiating the tumor part of the mouse for 10 min. The size of the tumor was measured in two dimensions by a vernier caliper every other day, the body weight of the tumor-bearing mice was measured, and the second administration treatment was performed on day 3. The formula for calculating the tumor volume is V ═ WL2And/2 (W represents the major diameter of the tumor and L represents the minor diameter of the tumor). On day 15, mice were sacrificed and tumor masses were isolated and weighed.
As shown in fig. 13, showing the in vivo combined anti-tumor results of example six, the targeted penetration type nanotechnology complex GM @ tLyP-1/Ce6 showed very significant tumor inhibition effect (fig. 13a), minimal final tumor volume and weight (fig. 13b), and no significant change in mouse body weight throughout the treatment process, compared to the GM @ PEG/Ce6 treated group and the GO @ tLyP-1/Ce6 treated group, indicating that GM @ tLyP-1/Ce6 has very good biosafety.
Claims (8)
1. The targeted penetrating nano diagnosis and treatment compound is characterized by comprising a GO-MnO2 composite oxygen-generating carrier taking graphene oxide as a substrate, tumor targeted homing penetrating peptides connected with the composite oxygen-generating carrier in a chemical covalent connection mode, and a photosensitizer connected with the composite oxygen-generating carrier in a pi-pi stacking effect, a hydrophobic effect, a hydrogen bond or an electrostatic effect;
the GO-MnO2 composite oxygen-generating carrier taking graphene oxide as a substrate is prepared by in-situ growing MnO2 nano particles on the surface of graphene oxide through modification of aminated cations;
the targeted penetrating type nano diagnosis and treatment compound for the in-situ oxygen generation and sensitization photodynamic curative effect of the tumor is prepared by the following method:
(1) synthesized GO-MnO2 composite oxygen generation type carrier
Carrying out self-assembly or amide reaction on GO and an aminated polycation polymer to prepare a GO-polycation compound, adding a potassium permanganate solution into the GO-polycation compound, and reacting at room temperature for 12-36h to prepare the GO-polycation compound; the mass ratio of the aminated polycationic polymer to GO is 0.25: 1-2: 1; the mass ratio of GO to potassium permanganate is 1: 8-12; the aminated polycationic polymer is poly (allylamine hydrochloride);
(2) preparation of targeting penetrating oxygen-producing nano composite carrier
Synthesizing FITC-labeled thiolated tumor targeted homing penetrating peptide, mixing GO-MnO2 composite oxygen-producing carrier, maleimide polyethylene glycol succinimide acetate and FITC-labeled thiolated tumor targeted homing penetrating peptide according to the weight ratio of 1:0.1-1:0.1-1, and reacting at room temperature for 20-28h to obtain the product;
(3) preparation of targeting penetrating nano diagnosis and treatment compound
The photosensitizer and the targeted penetrating oxygen-producing nano composite carrier are self-assembled to prepare the targeted penetrating nano diagnosis and treatment composite.
2. The tumor in-situ oxygenation-producing sensitization photodynamic therapy targeted penetration type nano diagnosis and treatment compound as claimed in claim 1, wherein the tumor targeted homing penetration peptide is LyP-1, F3, iRGD or tLyP-1.
3. The tumor in-situ oxygen generation and sensitization targeted penetration type nano diagnosis and treatment compound with photodynamic therapy effect according to claim 1, wherein the photosensitizer is organic fluorescent dye capable of generating singlet oxygen under the excitation of near infrared light.
4. The tumor in-situ oxygen production sensitization photodynamic therapy targeted penetration type nanometer diagnosis and treatment compound as claimed in claim 3, wherein the photosensitizer is chlorins, porphyrins, rhodamines, methylene blue or cyanine.
5. The tumor in-situ oxygen production sensitization photodynamic therapy targeted penetration type nano diagnosis and treatment compound as claimed in claim 1, wherein the mass ratio of the aminated polycation polymer to GO is 1: 1.
6. The tumor in-situ oxygenation sensitization photodynamic therapy targeted penetration type nano diagnosis and treatment compound as claimed in claim 1, wherein GO-MnO is2The weight ratio of the composite oxygen-producing carrier, the maleimide polyethylene glycol succinimide acetate and the FITC marked thiolated tumor targeting homing penetrating peptide is 1:0.18:0.18, and the thiolated tumor targeting homing penetrating peptide is thiolated tLyP-1.
7. The tumor in-situ oxygen generation and sensitization targeted penetration type nano diagnosis and treatment compound with photodynamic therapy effect according to claim 1 is characterized in that the mass ratio of the photosensitizer to the targeted penetration type oxygen generation nano compound carrier is 0.1-4: 1.
8. the tumor in-situ oxygen generation and sensitization targeted penetration type nano diagnosis and treatment compound with the photodynamic therapy effect according to claim 7 is characterized in that the mass ratio of the photosensitizer to the targeted penetration type oxygen generation nano compound carrier is 1: 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010771037.XA CN111821436B (en) | 2020-08-04 | 2020-08-04 | Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010771037.XA CN111821436B (en) | 2020-08-04 | 2020-08-04 | Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111821436A CN111821436A (en) | 2020-10-27 |
CN111821436B true CN111821436B (en) | 2021-10-08 |
Family
ID=72919329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010771037.XA Active CN111821436B (en) | 2020-08-04 | 2020-08-04 | Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111821436B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112451862B (en) * | 2020-11-24 | 2023-03-28 | 深圳罗兹曼国际转化医学研究院 | Photodynamic therapy system and control method thereof |
CN115317605B (en) * | 2022-08-15 | 2024-05-07 | 上海交通大学医学院 | Autonomous oxygen supply compound photosensitizer and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104183830A (en) * | 2014-08-19 | 2014-12-03 | 中南大学 | Preparation method of two-dimensional inorganic layered compound/graphene composite material |
CN107080850A (en) * | 2017-04-07 | 2017-08-22 | 中国科学院武汉物理与数学研究所 | A kind of RGD graphenes/MnO2The combined probe of magnetic nano-balls and its application |
CN107158405A (en) * | 2017-05-24 | 2017-09-15 | 电子科技大学 | A kind of photosensitive immune combination drug of Mitochondrially targeted nanometer and its preparation method and application |
CN107670040A (en) * | 2017-10-25 | 2018-02-09 | 深圳先进技术研究院 | Gold nanometer cage manganese dioxide composite nanometer particle and its preparation method and application |
CN109718384A (en) * | 2018-11-20 | 2019-05-07 | 广西医科大学 | Reduction response targeted nano graphene oxide drug carrier and preparation method and application |
-
2020
- 2020-08-04 CN CN202010771037.XA patent/CN111821436B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104183830A (en) * | 2014-08-19 | 2014-12-03 | 中南大学 | Preparation method of two-dimensional inorganic layered compound/graphene composite material |
CN107080850A (en) * | 2017-04-07 | 2017-08-22 | 中国科学院武汉物理与数学研究所 | A kind of RGD graphenes/MnO2The combined probe of magnetic nano-balls and its application |
CN107158405A (en) * | 2017-05-24 | 2017-09-15 | 电子科技大学 | A kind of photosensitive immune combination drug of Mitochondrially targeted nanometer and its preparation method and application |
CN107670040A (en) * | 2017-10-25 | 2018-02-09 | 深圳先进技术研究院 | Gold nanometer cage manganese dioxide composite nanometer particle and its preparation method and application |
CN109718384A (en) * | 2018-11-20 | 2019-05-07 | 广西医科大学 | Reduction response targeted nano graphene oxide drug carrier and preparation method and application |
Non-Patent Citations (5)
Title |
---|
A tumor-microenvironment fully responsive nano-platform for MRI-guided photodynamic and photothermal synergistic therapy;Daquan Wang等;《J. Mater. Chem. B》;20200725;第8卷;第8271-8281页 * |
An 808 nm Light-Sensitized Upconversion Nanoplatform for Multimodal Imaging and Effi cient Cancer Therapy;Arif Gulzar等;《Inorg. Chem.》;20200116;第A-O页 * |
FePt-Au异质结构控制合成及其作为诊疗探针应用研究;王金龙等;《中国化学会第30届学术年会 工程科技Ⅰ辑》;20160701;第1页 * |
Functional Graphene Oxide-Based Nanosheets for Photothermal Therapy;Jae Hyun Lim等;《Macromolecular Research》;20181231;第26卷(第6期);第557-565页 * |
多功能纳米材料用于影像指导的肿瘤治疗;刘秧;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20181115(第11期);第E072-26页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111821436A (en) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy | |
Wang et al. | Fabrication of red blood cell-based multimodal theranostic probes for second near-infrared window fluorescence imaging-guided tumor surgery and photodynamic therapy | |
Zhang et al. | Dendrimer grafted persistent luminescent nanoplatform for aptamer guided tumor imaging and acid-responsive drug delivery | |
Shen et al. | pH-responsive aerobic nanoparticles for effective photodynamic therapy | |
Yang et al. | Mesoporous silica nanorods intrinsically doped with photosensitizers as a multifunctional drug carrier for combination therapy of cancer | |
JP7372672B2 (en) | Complex of active pharmaceutical ingredients | |
Yang et al. | Tumor microenvironment (TME)-activatable circular aptamer-PEG as an effective hierarchical-targeting molecular medicine for photodynamic therapy | |
Ji et al. | Tandem activated photodynamic and chemotherapy: Using pH-Sensitive nanosystems to realize different tumour distributions of photosensitizer/prodrug for amplified combination therapy | |
Wang et al. | Enhanced-fluorescent imaging and targeted therapy of liver cancer using highly luminescent carbon dots-conjugated foliate | |
Wang et al. | pH-and NIR light responsive nanocarriers for combination treatment of chemotherapy and photodynamic therapy | |
Zhang et al. | pH-driven targeting nanoprobe with dual-responsive drug release for persistent luminescence imaging and chemotherapy of tumor | |
Li et al. | Light-enhanced hypoxia-responsive nanoparticles for deep tumor penetration and combined chemo-photodynamic therapy | |
KR101452819B1 (en) | Redox-responsive polymer-photosensitizer conjugate containing disulfide linker and its composition for fluorescence imaging and photodynamic therapy comprising thereof | |
Wu et al. | Nanobody modified high-performance AIE photosensitizer nanoparticles for precise photodynamic oral cancer therapy of patient-derived tumor xenograft | |
Thanasekaran et al. | Lipid-wrapped upconversion nanoconstruct/photosensitizer complex for near-infrared light-mediated photodynamic therapy | |
CN111821436B (en) | Targeted penetrating type nano diagnosis and treatment compound for in-situ tumor oxygen generation and sensitization photodynamic curative effect and construction method thereof | |
Zhang et al. | A multifunctional nanoplatform based on graphitic carbon nitride quantum dots for imaging-guided and tumor-targeted chemo-photodynamic combination therapy | |
Wang et al. | Lipid coated upconverting nanoparticles as NIR remote controlled transducer for simultaneous photodynamic therapy and cell imaging | |
Sun et al. | Ce6-C6-TPZ co-loaded albumin nanoparticles for synergistic combined PDT-chemotherapy of cancer | |
Zhao et al. | Buffet-style Cu (II) for enhance disulfiram-based cancer therapy | |
Keum et al. | Photomedicine based on heme-derived compounds | |
Lin et al. | A phthalocyanine-based liposomal nanophotosensitizer with highly efficient tumor-targeting and photodynamic activity | |
Zhang et al. | Synthesis and biomedical application of nanocomposites integrating metal-organic frameworks with upconversion nanoparticles | |
Harvey et al. | Recent advances in nanoscale metal–organic frameworks towards cancer cell cytotoxicity: an overview | |
Dong et al. | GQDs/hMSN nanoplatform: Singlet oxygen generation for photodynamic therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |